05:44 AM EDT, 06/30/2025 (MT Newswires) -- (Updates with GSK's response.)

Sen. Maggie Hassan (D-N.H.) said she is opening an investigation into GSK's (GSK) decision to discontinue a widely used asthma inhaler for children, Reuters reported Friday, citing a letter sent by the senator to the company it has seen.

"We have taken steps to make the authorized generic, or AG, and our other inhalers more accessible," a GSK spokesperson said in a statement e-mailed to MT Newswires. "In May 2022, nearly 30 years after Flovent entered the market, we launched an authorized generic of Flovent HFA, through Prasco. However, since the launch of the AG, there have been external factors impacting patient access to the product."

GSK said it is supporting a patient assistance program launched by Prasco in December "to provide free products to eligible patients who are not able to afford their medicine."

"In addition, GSK launched a pay no more than $35 program for all of GSK's 9 marketed inhalers in the US which provides a significant benefit to eligible commercially insured and cash paying patients, reducing their out-of-pocket costs per inhaler to no more than $35 a month," said the GSK spokesperson.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)